Topics in this section

Hepatitis and HIV: latest news

Hepatitis and HIV resources

Hepatitis and HIV features

Hepatitis and HIV in your own words

Hepatitis and HIV news from aidsmap

More news

Hepatitis and HIV news selected from other sources

  • Coffee, Even Decaf, May Promote Liver Health

    Drinking coffee, whether decaffeinated or regular, is linked to healthier levels on tests indicating liver function.

    16 October 2014 | AIDSMeds
  • IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials

    AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek 2014 last week in Philadelphia. Serious side effects were uncommon and few people discontinued treatment for this reason.

    16 October 2014 | HIVandHepatitis.com
  • Investigating an outbreak of hepatitis C virus among MSM without HIV

    Given the reports about the high-risk practices taking place in London (and likely other cities in high-income countries), it is likely that cases of sexually transmitted HCV are also occurring in some HIV-negative MSM. To investigate this possibility, researchers in London reviewed health-related information collected from HIV-negative patients who sought care at selected clinics in that city.

    01 October 2014 | CATIE
  • Study Dampens HOPE of HIV Organ Donations

    The HIV Organ Policy Equity (HOPE) Act, which legalizes research into organ tranplants from HIV-positive donors to HIV-positive recipients, is less than a year old, but a new study already suggests the organs may be of poor quality.

    17 September 2014 | Medscape (requires registration)
  • Uncovering cases of early HCV infection in HIV-positive men

    While screening the blood samples of patients for HCV antibodies can be useful, a new study suggests that in some cases such antibodies may not appear for several months after HCV infection has occurred. In such cases, acute HCV infection might be missed if antibody tests alone are used for screening - RNA testing should be used to screen HCV infection.

    17 September 2014 | CATIE
  • US: HIV medical organizations challenge insurer restrictions to HCV treatment

    The American Academy of HIV Medicine (AAHIVM) and the HIV Medicine Association (HIVMA), the two largest professional associations representing HIV clinicians in the U.S., are challenging new health plan cost control policies barring many qualified HIV care providers from prescribing certain medications that treat hepatitis C (HCV).

    04 September 2014 | EATG / AAHIVM / HIVMA
  • European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

    Bristol-Myers Squibb Company today announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults. Daklinza, when used in combination with sofosbuvir (Sovaldi), is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials

    27 August 2014 | Bristol-Myers Squibb
  • In patients co-infected with HIV, combination antiretroviral therapy helps treat HCV

    Treatment of HIV patients co-infected with the hepatitis C virus (HCV) with an anti-retroviral drug therapy not only tackles HIV, but also reduces HCV replication, according to a new study lead by a University of Cincinnati researcher. The results were published in Science Translational Medicine.

    25 July 2014 | HIV / AIDS News From Medical News Today
  • US: Studies look at hepatitis C care cascade and healthcare utilization

    Half of people with hepatitis C in the U.S. are aware of their infection, but fewer than 10% have been successfully treated and achieved sustained virological response (SVR), according to a meta-analysis published July 2 in the open-access journal PLoS ONE.

    08 July 2014 | HIVandHepatitis.com
  • Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen

    Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza® (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), and Sunvepra® (asunaprevir), a NS3/4A protease inhibitor.

    08 July 2014 | Bristol-Myers Squibb press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also